Guided Therapeutics (GTHP) Non Operating Interest Expenses (2010 - 2026)

Guided Therapeutics has disclosed Non Operating Interest Expenses across 17 years of filings, most recently posting $136000.0 for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses fell 13.38% year-over-year to $136000.0; the TTM figure through Jun 2026 stood at $600000.0 (up 9.89% YoY), while the FY2025 annual figure was $617000.0, up 61.94% from the prior year.
• Non Operating Interest Expenses came in at $136000.0 for Q2 2026 at Guided Therapeutics, down from $151000.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $256000.0 in Q2 2022 to a low of $64000.0 in Q1 2024.
• Average Non Operating Interest Expenses over 5 years is $119166.7, with a median of $118500.0 recorded in 2024.
• Year-over-year, Non Operating Interest Expenses plunged 73.91% in 2022 and surged 129.69% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $70000.0 in 2022, then advanced by 2.86% to $72000.0 in 2023, then jumped by 86.11% to $134000.0 in 2024, then jumped by 37.31% to $184000.0 in 2025, then decreased by 26.09% to $136000.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $136000.0 in Q2 2026, $151000.0 in Q1 2026, and $184000.0 in Q4 2025.